65.9 F
Pakistan
Friday, October 23, 2026
HomeHealthParadigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for...

Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa

SD-101 (Zorblesia™) is the First Topical Therapy Being Developed to Treat Wounds and Lesions Across the Entire Skin Surface in Patients with Three Major Subtypes of Epidermolysis Bullosa MOUNT PLEASANT, S. C. , Oct. 22, 2026 /PRNewswire/ — Paradigm Therapeutics, Inc. , a clinical-stage. ..

Read full story on Pr Newswire Apac

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -
Google search engine

Most Popular

Recent Comments